Zylox-Tonbridge's CEO, Dr. Jonathon Zhong Zhao, highlighted a transformative year for the company, with product innovation, improved operational efficiency, and strategic focus on leveraging Volume Based Procurement (VBP) opportunities enabling accelerated growth and profitability. The company plans to continue expanding its innovative product portfolio and improving operational efficiency in the future.

CEO of Everest Medicines, Rogers Yongqing Luo, is confident that the appointments of Ms. Zeng and Mr. Liang will expedite the company's strategic growth. They are anticipated to spearhead their teams and foster strategic integration, promoting successful commercialization of Everest's products and long-term value creation.

CStone Pharmaceuticals' lower P/S ratio is due to its perceived limited future growth. Analysts' inferior revenue outlook contributes to its low P/S, making a significant share price rise unlikely soon.

Analysts predict Ocumension Therapeutics will reach breakeven before exhausting its cash reserves. Positive revenue growth is noted, but cash burn reduction is seen as a weak point. The company is considered well-positioned to raise more cash for growth if necessary.